| Schedule of Segment Reporting Information |
The measure of profit for the segment is net (loss) income and consisted of the following for the three and six months ended June 30, 2025, and 2024: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | (in thousands) | 2025 | | 2024 | | 2025 | | 2024 | | Revenue from external customers | $ | 1,973 | | | $ | 563 | | | $ | 30,780 | | | $ | 563 | | | Compensation expense, excluding stock-based compensation, SARs compensation expense and severance expense | 9,903 | | | 11,639 | | | 21,473 | | | 22,224 | | | Direct research and development program expenses (X4P-001, mavorixafor) | 9,413 | | | 10,742 | | | 17,825 | | | 21,408 | | | Gain on sale of non-financial assets | — | | | (105,000) | | | — | | | (105,000) | | | Other segment items (a) | 8,398 | | | (7,651) | | | 16,941 | | | 22,864 | | | Net (loss) income (measure of segment profit) | $ | (25,741) | | | $ | 90,833 | | | $ | (25,459) | | | $ | 39,067 | |
|